Home
News
Create
Screeners
Insights
Astonea Labs
159.
00
-159.00
(-100.00%)
Market Cap
₹167.10 Cr
PE Ratio
31.24
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-100.00%
1M
-100.00%
6M
-100.00%
1Y
-100.00%
5Y
-100.00%
View Company Insights
Latest news about Astonea Labs
Astonea Labs Board Approves IPO Proceeds Variation and Related Party Transactions Worth Rs. 415 Crore
Feb 27, 2026
Astonea Labs Limited's board approved variation in IPO proceeds utilization of Rs. 6.25 crore for acquiring 20-21% stake in Damaira Pharmaceuticals Private Limited, representing 16.59% deviation from original objects. The board also granted omnibus approval for material related party transactions worth Rs. 415 crore for FY 2026-27, with major transactions planned with Astonea One Private Limited and other related entities. An Extraordinary General Meeting has been scheduled for 27th March, 2026, to seek shareholder approval for these proposals along with adoption of new Articles of Association and other corporate matters.
Astonea Labs Limited Incorporates Wholly-Owned US Subsidiary for Pharmaceutical Business Expansion
Jan 26, 2026
Astonea Labs Reports Strong Half-Year Results and Appoints Three New Directors
Nov 11, 2025
Astonea Labs' Company Secretary Resigns, Trading Window to Close
Sep 20, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO